International Journal of

ADVANCED AND APPLIED SCIENCES

EISSN: 2313-3724, Print ISSN: 2313-626X

Frequency: 12
line decor
  
line decor

 Volume 8, Issue 3 (March 2021), Pages: 112-119

----------------------------------------------

 Original Research Paper

 Title: The potential interaction of statins and clopidogrel in patients undergoing percutaneous coronary intervention

 Author(s): Tahani H. Ibrahim 1, Hind S. Alanazy 2, *, Maram M. Alharbi 2, Safa M. Ahmed 3

 Affiliation(s):

 1Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Al Qassim, Saudi Arabia
 2College of Pharmacy, Qassim University, Al Qassim, Saudi Arabia
 3Prince Sultan Cardiac Center, Al Qassim, Saudi Arabia

  Full Text - PDF          XML

 * Corresponding Author. 

  Corresponding author's ORCID profile: https://orcid.org/0000-0002-7301-0600

 Digital Object Identifier: 

 https://doi.org/10.21833/ijaas.2021.03.014

 Abstract:

Clopidogrel is widely used for patients with acute coronary syndrome. It is a pro-drug that requires bioactivation by several cytochrome P450 (CYP) enzymes, mainly CYP3A4, CYP2C9, and CYP2C19 enzymes. Lipophilic statins such as atorvastatin are used concomitantly with clopidogrel due to their beneficial effects on morbidity and mortality in the arena of cardiovascular diseases. However, lipophilic statins are eliminated by CYP3A4 and undergo the same metabolic pathway of clopidogrel. Hence, statins may compete with clopidogrel for CYP3A4 enzyme resulting in diminishing the anti-platelet effect of clopidogrel. We aimed to study the impact of concomitant statin therapy on clopidogrel efficacy in patients undergoing percutaneous coronary intervention (PCI) evaluate the clinical relevance of potential clopidogrel and statins interaction and association between use of statins and risk of future adverse cardiac events. A cross-sectional retrospective cohort study was conducted on 50 patients attending Prince Sultan Cardiac Center for follow-up after PCI. All patients discharged on clopidogrel, aspirin, and atorvastatin were later divided into two groups according to the occurrence of MACEs. Statistical analysis was performed by Statistical Package for the Social Science (SPSS; V. 21.0). This study was on adult and geriatric males and female (28%). More than half of them exhibited major adverse cardiac events (MACEs), of which 48% exhibited it after 4 to 6 months from PCI indexing followed by 1 to 3 months , and the least after 7 to 9 months. A significant association arises between gender and MACEs (P 0.042). Moreover, the average age was significantly higher in patients who experience MACEs compared to others (62.7 vs. 55.4, P 0.037). Regarding comorbidities, hypertension increased in patients with MACEs  compared to those without MACEs . The average duration of taking clopidogrel was significantly shorter in patients with MACEs compared to those who did not (3.42 vs. 5.54 months, P 0.001). According to the findings of this study, atorvastatin affects clopidogrel efficacy in patients undergoing PCI. 

 © 2021 The Authors. Published by IASE.

 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

 Keywords: Clopidogrel, Cardiovascular disease, Adverse cardiac events, Statins

 Article History: Received 15 August 2020, Received in revised form 23 November 2020, Accepted 27 November 2020

 Acknowledgment:

No Acknowledgment.

 Compliance with ethical standards

 Ethical considerations: The study was ethically approved by the Qassim Research Ethics Committee and the ethical committee of the hospital.

 Conflict of interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

 Citation:

  Ibrahim TH, Alanazy HS, and Alharbi MM et al. (2021). The potential interaction of statins and clopidogrel in patients undergoing percutaneous coronary intervention. International Journal of Advanced and Applied Sciences, 8(3): 112-119

 Permanent Link to this page

 Figures

 Fig. 1 Fig. 2 Fig. 3 Fig. 4

 Tables

 Table 1 Table 2 Table 3 Table 4 Table 5

----------------------------------------------

 References (30)

  1. Al Ahmari AS, Alsbhani WM, Al Hamad MA, Al Hamad SA, Sakabomi DM, Aljehani SM, and Alotibi MS (2017). Prevalence of risk factors for coronary heart disease among patients presented in cardiology clinic at king Abdul-Aziz hospital and oncology Center–Jeddah. The Egyptian Journal of Hospital Medicine, 68(2): 1101-1106. https://doi.org/10.12816/0039036   [Google Scholar]
  2. An K, Huang R, Tian S, Guo D, Wang J, Lin H, and Wang S (2019). Statins significantly reduce mortality in patients receiving clopidogrel without affecting platelet activation and aggregation: A systematic review and meta-analysis. Lipids in Health and Disease, 18: 121. https://doi.org/10.1186/s12944-019-1053-0   [Google Scholar] PMid:31122249 PMCid:PMC6533696
  3. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, and Mikhailidis DP (2009). Pleiotropic effects of statins-clinical evidence. Current Pharmaceutical Design, 15(5): 479-489. https://doi.org/10.2174/138161209787315729   [Google Scholar] PMid:19199976
  4. Bates ER, Lau WC, and Angiolillo DJ (2011). Clopidogrel–drug interactions. Journal of the American College of Cardiology, 57(11): 1251-1263. https://doi.org/10.1016/j.jacc.2010.11.024   [Google Scholar] PMid:21392639
  5. Beaird SL (2000). HMG-CoA reductase inhibitors: Assessing differences in drug interactions and safety profiles. Journal of the American Pharmaceutical Association (1996), 40(5): 637-644. https://doi.org/10.1016/S1086-5802(16)31104-4   [Google Scholar]
  6. Brophy JM, Babapulle MN, Costa V, and Rinfret S (2006). A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. American Heart Journal, 152(2): 263-269. https://doi.org/10.1016/j.ahj.2005.08.023   [Google Scholar] PMid:16875906
  7. Burkard T, Kaiser CA, Brunner‐La Rocca H, Osswald S, Pfisterer ME, Jeger RV, and BASKET Investigators (2012). Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: A report from the BASKET trial. Journal of Internal Medicine, 271(3): 257-263. https://doi.org/10.1111/j.1365-2796.2011.02423.x   [Google Scholar] PMid:21726302
  8. Cheung BM, Lauder IJ, Lau CP, and Kumana CR (2004). Meta‐analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. British Journal of Clinical Pharmacology, 57(5): 640-651. https://doi.org/10.1111/j.1365-2125.2003.02060.x   [Google Scholar] PMid:15089818 PMCid:PMC1884492
  9. Chinwong D, Patumanond J, Chinwong S, Siriwattana K, Gunaparn S, Hall JJ, and Phrommintikul A (2015). Statin therapy in patients with acute coronary syndrome: Low-density lipoprotein cholesterol goal attainment and effect of statin potency. Therapeutics and Clinical Risk Management, 11: 127-136. https://doi.org/10.2147/TCRM.S75608   [Google Scholar] PMid:25670902 PMCid:PMC4315463
  10. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, and Gawaz M (2008). The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. Journal of Thrombosis and Haemostasis, 6(1): 54-61. https://doi.org/10.1111/j.1538-7836.2007.02812.x   [Google Scholar] PMid:17949474
  11. Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, and Gawaz M (2006). Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. European Heart Journal, 27(20): 2420-2425. https://doi.org/10.1093/eurheartj/ehl275   [Google Scholar] PMid:17005534
  12. Hernandez-Suarez DF, Tomassini-Fernandini JC, Cuevas A, Rosario-Berrios AN, Nuñez-Medina HJ, Padilla-Arroyo D, and Melin K (2018). Clinical relevant polymorphisms affecting clopidogrel pharmacokinetics and pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program. International Journal of Environmental Research and Public Health, 15(6): 1115. https://doi.org/10.3390/ijerph15061115   [Google Scholar] PMid:29848980 PMCid:PMC6025039
  13. Júnior SCV, Soeiro ADM, Araújo LF, Jabot B, Rached F, Orii NM, and Ramires JAF (2010). Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation. Arquivos Brasileiros de Cardiologia, 95(3): 321-327. https://doi.org/10.1590/S0066-782X2010005000106   [Google Scholar] PMid:20721515
  14. Kleib BLS, Alhoshan AA, and Alolayah AM (2018). Risk factors of coronary heart disease among medical students in Almaarefa colleges, Riyadh, Saudi Arabia. The Egyptian Journal of Hospital Medicine, 31(5623): 1-11.   [Google Scholar]
  15. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, and Bates ER (2003). Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug–drug interaction. Circulation, 107(1): 32-37. https://doi.org/10.1161/01.CIR.0000047060.60595.CC   [Google Scholar] PMid:12515739
  16. Lin MJ, Chen CY, Lin HD, and Wu HP (2017). Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention. BMC Cardiovascular Disorders, 17: 12. https://doi.org/10.1186/s12872-016-0454-5   [Google Scholar] PMid:28056847 PMCid:PMC5217339
  17. Liu X, He X, Wu J, and Luo D (2019). Initiation and persistence with antiplatelet agents among the patients with acute coronary syndromes: A retrospective, observational database study in China. Patient Preference and Adherence, 13: 2159–2169. https://doi.org/10.2147/PPA.S228065   [Google Scholar] PMid:31908423 PMCid:PMC6925556
  18. Malmström RE, Östergren J, Jørgensen L, Hjemdahl P, and CASTOR Investigators (2009). Influence of statin treatment on platelet inhibition by clopidogrel-A randomized comparison of rosuvastatin, atorvastatin and simvastatin co‐treatment. Journal of Internal Medicine, 266(5): 457-466. https://doi.org/10.1111/j.1365-2796.2009.02119.x   [Google Scholar] PMid:19549094
  19. Movahed MR, Hashemzadeh M, Jamal MM, and Ramaraj R (2010). Decreasing in-hospital mortality of patients undergoing percutaneous coronary intervention with persistent higher mortality rates in women and minorities in the United States. The Journal of Invasive Cardiology, 22(2): 58-60.   [Google Scholar]
  20. Nagavi JB, Gurupadayya B, and Anantharaju PG (2016). Omeprazole and atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation in patients undergoing percutaneous coronary intervention in a tertiary health care system: A prospective drug–drug interaction study. IJC Metabolic and Endocrine, 13: 35-40. https://doi.org/10.1016/j.ijcme.2016.09.004   [Google Scholar]
  21. Nassr OA, Forsyth P, and Johnson CF (2019). Evaluation of discharge prescriptions for secondary prevention in patients with acute coronary syndromes in Iraq. Pharmacy Practice (Granada), 17(1): 1372. https://doi.org/10.18549/PharmPract.2019.1.1372   [Google Scholar] PMid:31015874 PMCid:PMC6463406
  22. Park JS, Cha KS, Lee HW, Oh JH, Choi JH, Lee HC, and HOST–ASSURE Investigators (2017). Platelet reactivity and clinical outcomes in patients using CYP3A4-metabolized statins with clopidogrel in percutaneous coronary intervention. Heart and Vessels, 32(6): 690-699. https://doi.org/10.1007/s00380-016-0927-6   [Google Scholar] PMid:27904973
  23. Roghani-Dehkordi F, Hashemifard O, Sadeghi M, Mansouri R, Akbarzadeh M, Dehghani A, and Akbari M (2018). Distal accesses in the hand (two novel techniques) for percutaneous coronary angiography and intervention. ARYA Atherosclerosis, 14(2): 95-100.   [Google Scholar]
  24. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, and Herbert JM (2000). Identification and biological activity of the active metabolite of clopidogrel. Thrombosis and Haemostasis, 84(11): 891-896. https://doi.org/10.1055/s-0037-1614133   [Google Scholar] PMid:11127873
  25. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, and Topol EJ (2003). Lack of adverse clopidogrel–atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation, 108(8): 921-924. https://doi.org/10.1161/01.CIR.0000088780.57432.43   [Google Scholar] PMid:12925453
  26. Schmidt M, Johansen MB, Maeng M, Kaltoft A, Jensen LO, Tilsted HH, and Sørensen HT (2012). Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation. British Journal of Clinical Pharmacology, 74(1): 161-170. https://doi.org/10.1111/j.1365-2125.2012.04169.x   [Google Scholar] PMid:22243420 PMCid:PMC3394141
  27. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, and Hennekens CH (2004). Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study. Archives of Internal Medicine, 164(18): 2051-2057. https://doi.org/10.1001/archinte.164.18.2051   [Google Scholar] PMid:15477442
  28. Singh M, Rihal CS, Gersh BJ, Roger VL, Bell MR, Lennon RJ, and Holmes DR (2008). Mortality differences between men and women after percutaneous coronary interventions: A 25-year, single-center experience. Journal of the American College of Cardiology, 51(24): 2313-2320. https://doi.org/10.1016/j.jacc.2008.01.066   [Google Scholar] PMid:18549915 PMCid:PMC2733245
  29. Sotiriou CG and Cheng JW (2000). Beneficial effects of statins in coronary artery disease-Beyond lowering cholesterol. Annals of Pharmacotherapy, 34(12): 1432-1439. https://doi.org/10.1345/aph.10124   [Google Scholar] PMid:11144702
  30. Tang C, Qian H, Wang D, Qiao Y, and Yan G (2019). Prognostic value of serum Total bilirubin after percutaneous coronary intervention in patients with acute coronary syndrome. BioMed Research International, 2019: 5243589. https://doi.org/10.1155/2019/5243589   [Google Scholar] PMid:31275974 PMCid:PMC6558622